ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: All together, these data indicate that DOK proteins act as tumor suppressors through the inhibition of the RAS-MEK-ERK pathway, but in CML their function is directly inhibited by BCR-ABL (Fig. 2).